BBI Group establishes a centralised solution for diagnostic critical reagents & development service

CARDIFF, Wales - May 1, 2013 - PRLog -- Cardiff, UK, May 1, 2013: The BBI Group announces that from today, May 1st 2013, four of its core business entities BBInternational, BBI Enzymes, Scipac and Vision Biotech will merge and trade under one brand - BBI Solutions. BBI Solutions will trade alongside BBI Detection and BBI Healthcare as a separate division. As part of this restructure, a new brand identity will be rolled out across all aspects of business communications for all three divisions.

Speaking from the BBI Group’s headquarters in Cardiff, UK, Lyn Rees, Group CEO says: "This is a very exciting time in our company's development. BBI is a name that is synonymous with quality reagents and services and over the past 10 years we have grown significantly and brought a number of high quality organisations into BBI. This is an opportunity for us to bring the strength of these companies into one brand with global sites offering critical reagents and services to the diagnostic, pharmaceutical and consumer healthcare markets.

This development is part of our ongoing strategy to expand our global business in the area of immunoassay design, development and manufacture, while also offering an expanding portfolio of critical reagents, biological products and technologies for a variety of platforms servicing the global diagnostic and pharmaceutical markets.”

Customers of BBI Solutions will now benefit from a streamlined organizational structure. There will be single point access to BBI Solutions’ wide portfolio of biological reagents and immunoassay labels through a web based e-commerce site and an experienced and dedicated account team that can provide support across the entire portfolio of products. Customers can also be assured that the high emphasis on Quality Assurance and Quality Control for which all BBI Group companies are renowned will remain a priority.

Lyn Rees continues ”Our aim is to provide customers with the ability to make their strategic purchases conveniently and safe in the knowledge that they have a strong supply partner that can meet the majority, if not all, of their critical reagent needs both in terms of quality, economy and scale”.  

By offering an expanding portfolio of critical reagents and services, the aim of BBI Solutions is to be the number one total diagnostic solution partner for today and tomorrow’s highly accurate, highly reliable point of use diagnostic assays.

- ends –

Enquiries:
Julie Hart. BBI Solutions. Tel: +44 (0) 2920 747232
E-mail: info@bbisolutions.com
www.bbisolutions.com

UK Press Contact:
Eileen Holmes-Ievers. In Press Public Relations Ltd.  Tel: +44 (0)1488 674200
E-mail: eileen@inpress.co.uk        
Twitter: twitter.com/InPressPR

101BBI
May 1, 2013